Reactions of clinical neuropsychologists to the Alzheimer's Association workgroup's draft diagnostic and staging criteria for Alzheimer's disease

被引:0
作者
Kiselica, Andrew M. [1 ]
Atkins, Kelly J. [2 ,3 ]
Han, S. Duke [4 ]
Diaz-Orueta, Unai [5 ]
Gogniat, Marissa A. [6 ]
Blanco-Campal, Alberto [7 ,8 ]
Hermann, Greta [9 ]
Duff, Kevin [10 ]
机构
[1] Univ Georgia, Inst Gerontol, Athens, GA 30602 USA
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[3] Monash Univ, Sch Psychol, Melbourne, Australia
[4] Univ Southern Calif, Dept Psychol, Los Angeles, CA USA
[5] Maynooth Univ, Dept Psychol, Maynooth, Ireland
[6] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA USA
[7] Mental Hlth Serv Older Adult, Hlth Serv Execut, Limerick, Ireland
[8] Mater Misericordiae Univ Hosp, Dublin Neurol Inst, Dublin, Ireland
[9] Univ Missouri, Dept Hlth Psychol, Columbia, MO USA
[10] Oregon Hlth & Sci Univ, Oregon Alzheimers Dis Res Ctr, Dept Neurol, Portland, OR USA
关键词
Alzheimer's disease; biomarkers; clinical syndrome; diagnostic criteria; neuropsychology; staging; MILD COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; RECOMMENDATIONS; BIOMARKERS; GUIDELINES;
D O I
10.1177/13872877241292089
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: An Alzheimer's Association (AA) workgroup published criteria for the diagnosis and staging of Alzheimer's disease (AD). To date, there have not been empirical investigations of professionals' opinions regarding the AA criteria for AD. Objective: Our goal was to survey clinical neuropsychologists with expertise in dementia about these criteria. Methods: Participants were recruited from a professional interest group of neuropsychologists focused on dementia. They rated their agreement with 15 statements about the AA draft criteria for AD prior to publication of the final version. The 15 statements were rated on a 4-point Likert scale ranging from 1 = Strongly Disagree to 4 = Strongly Agree. Results: Sixty-one respondents provided analyzable data. When all 15 statements were coded such that higher values suggested more concern about the recommendations, the mean rating was 3.12 (SD = 0.36), suggesting that overall respondents had modest concerns about the recommendations. The statements that yielded the most concern focused on barriers to the implementation of the recommendations, including a lack of healthcare resources and costs of biomarker testing. Conversely, participants were equivocal about the criteria being a positive step forward and had mixed opinions about the applicability of these criteria to diverse groups. Conclusions: Opinions of neuropsychologists suggest the need for important revisions or additions to the AA criteria for AD, including a clearer statement of purpose and more guidance on practical implementation.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 50 条
  • [21] Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease
    Edmonds, Emily C.
    Delano-Wood, Lisa
    Galasko, Douglas R.
    Salmon, David P.
    Bondi, Mark W.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (01) : 231 - 242
  • [22] Revised criteria for the diagnosis and staging of Alzheimer's disease
    Jack Jr, Clifford R.
    Andrews, Scott J.
    Beach, Thomas G.
    Buracchio, Teresa
    Dunn, Billy
    Graf, Ana
    Hansson, Oskar
    Ho, Carole
    Jagust, William
    McDade, Eric
    Molinuevo, Jose Luis
    Okonkwo, Ozioma C.
    Pani, Luca
    Rafii, Michael S.
    Scheltens, Philip
    Siemers, Eric
    Snyder, Heather M.
    Sperling, Reisa
    Teunissen, Charlotte E.
    Carrillo, Maria C.
    NATURE MEDICINE, 2024, 30 (08) : 2121 - 2124
  • [23] Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens
    Paraskevaidi, Maria
    Allsop, David
    Karim, Salman
    Martin, Francis L.
    Crean, StJohn
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [24] Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic
    Duits, Flora H.
    Prins, Niels D.
    Lemstra, Afina W.
    Pijnenburg, Yolande A. L.
    Bouwman, Femke H.
    Teunissen, Charlotte E.
    Scheltens, Philip
    van der Flier, Wiesje M.
    ALZHEIMERS & DEMENTIA, 2015, 11 (05) : 523 - 532
  • [25] Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research
    Bieger, Andrei
    Brum, Wagner S.
    Borelli, Wyllians V.
    Therriault, Joseph
    De Bastiani, Marco A.
    Moreira, Amanda G.
    Benedet, Andrea L.
    Ferrari-Souza, Joao Pedro
    Da Costa, Jaderson C.
    Souza, Diogo O.
    Castilhos, Raphael M.
    Schuh, Artur Francisco Schumacher
    Chaves, Marcia L. Fagundes
    Schoell, Michael
    Zetterberg, Henrik
    Blennow, Kaj
    Pascoal, Tharick A.
    Gauthier, Serge
    Rosa-Neto, Pedro
    Schilling, Lucas P.
    Zimmer, Eduardo R.
    NEUROLOGY, 2024, 103 (05)
  • [26] The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey
    Caprioglio, Camilla
    Garibotto, Valentina
    Jessen, Frank
    Froelich, Lutz
    Allali, Gilles
    Assal, Frederic
    Frisoni, Giovanni B.
    Altomare, Daniele
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 89 (02) : 535 - 551
  • [27] The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome
    Guo, Liang-Hao
    Alexopoulos, Panagiotis
    Eisele, Tamara
    Wagenpfeil, Stefan
    Kurz, Alexander
    Perneczky, Robert
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2013, 263 (04) : 325 - 333
  • [28] Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers
    Empar Blanco-Canto, Maria
    Monge-Argiles, J. A.
    Perez-Cejuela, C.
    Badia, C.
    Gabaldon, L.
    Munoz-Ruiz, C.
    Sanchez-Paya, J.
    Gasparini-Berenguer, R.
    Leiva-Santana, C.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2017, 32 (02): : 101 - 107
  • [29] Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria
    Wimo, A.
    Ballard, C.
    Brayne, C.
    Gauthier, S.
    Handels, R.
    Jones, R. W.
    Jonsson, L.
    Khachaturian, A. S.
    Kramberger, M.
    JOURNAL OF INTERNAL MEDICINE, 2014, 275 (03) : 304 - 316
  • [30] The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
    Cummings, Jeffrey
    ALZHEIMERS & DEMENTIA, 2019, 15 (01) : 172 - 178